he results of the mir31-3p expression analysis in the FIRE-3 colon cancer study will be presented on June 4 at the 2016 ASCO Annual Meeting in Chicago, during a poster discussion session. From more than 5,800 abstracts received, the ASCO Scientific Committee retained only a small number, and only a fraction were selected for the discussion sessions due to their scientific interest and the potential impact of the results. This underlines the importance of the results of this miR-31-3p study in patients with metastatic colorectal cancer. The results are embargoed until the date of presentation. Detailed information on the results of this study will be communicated after their presentation.

Link to publication: http://abstracts.asco.org/176/AbstView_176_164492.html